IMAJ | volume 24
Journal 12, December 2022
1 Pulmonary Institute, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel
2 Department of Internal Medicine H, Shamir Medical Center (Assaf Harofeh), Zerifin, Israel
3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Severe asthma affects up to 20,000 citizens of Israel. Novel biological therapies, which individually have been proven to reduce asthma morbidity in clinical trials, have become available in recent years. Comparative data among different drugs are scarce.
To describe and compare the clinical outcomes of biological therapies in severe asthma patients treated at Shamir Medical Center.
We conducted a cohort study based on a review of cases treated with monoclonal antibodies for severe asthma at our center. Data were extracted for demographics, eosinophil count, lung function (FEV1), exacerbation rate, and median dose of oral prednisone. Between-drug comparison was conducted by repeated measures ANOVA.
The cohort included 62 patients receiving biological therapy. All biologic drugs were found to reduce exacerbation rate [F(1, 2) = 40.4, P
< 0.0001] and prednisone use [F(1, 4) = 16, P
< 0.001] significantly. ANOVA revealed no difference of efficacy endpoints between the different drugs. Eosinophil count was significantly reduced post-biologic treatment in the anti-interleukin-5 agents (P
< 0.001) but not under treatment with omalizumab and dupilumab.
All of the biological therapies were effective for improving clinical outcomes. None of the agents was clearly superior to any other. These data emphasize the need for severe asthma patients to be seen by pulmonary medicine specialists and offered, where appropriate, biological therapies.